CyGenics Expands Into Europe
Plans to acquire stake in PharmaCell
Through this investment CyGenics will be able to build on PharmaCell's know-how and resources for product and process design, and utilise the PharmaCell GMP manufacturing facility. Strategically, this investment will give CyGenics access to a state of the art GMP manufacturing facility that can provide the high quality standards required by the new European directive for cord blood banking. The investment also vertically integrates the service offerings of CyGenics from adult stem cell storage services and cell growth consumables products to include cell therapy manufacturing services.
PharmaCell and CyGenics are two partners in the multi-national PACRIMA R&D collaboration. The mandate of PACRIMA is to develop a platform for growing antigen specific T cells and to test whether these cells are suitable for therapeutic use in the treatment of cancer. PACRIMA has been awarded a EUR1,000,000 (approximately A$1.7 million) grant from the Dutch Ministry of Economic Affairs to foster international collaboration of Dutch organisations in research and development.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.